Advancing Alzheimer’s Disease Detection Through Blood-Based Biomarkers

On-Demand Recording


Thanks for your interest in our recent webinar in partnership with Science.

Phosphorylated tau (p-Tau), amyloid-beta (Ab) 42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are current key Alzheimer’s disease (AD) blood-based biomarkers. Interpreting results of the four biomarkers simultaneously in a clinical context is challenging due to issues such as tissue sample size, cost, and timing. A decision algorithm could aid in the interpretation, tailored to clinically relevant questions: 1) identify positive amyloid status among preclinical and prodromal AD stages, 2) discriminate AD-dementia from frontotemporal dementia (FTD), and 3) characterize AD-dementia from dementia with Lewy bodies (DLB).

This webinar discussed the development and validation of such an interpretation tool and demonstrated that the combination of p-Tau 181, GFAP, and NfL in plasma could support decision making in different clinical contexts and serve as a tool to support both detection and differential diagnosis of Alzheimer’s disease.

Viewers will:

  • Learn about current and upcoming blood-based biomarkers for Alzheimer’s disease and other neuropsychiatric syndromes
  • Gain insight on how multiple biomarkers are needed to sort out the complexities of AD, co-pathologies, and non-AD dementias
  • Hear about the advantages and disadvantages of using these biomarkers for research and clinical correlations
  • Have an opportunity to ask questions during the live broadcast


Inge Verberk, Ph.D.

Amsterdam University Medical Centers, Amsterdam, The Netherlands

Dr. Verberk is a senior researcher at the Neurochemistry Lab of Amsterdam UMC, Amsterdam, The Netherlands. Her research focuses on the development and implementation of blood-based biomarkers for the diagnosis and prognosis of Alzheimer’s disease.

By submitting this form, you agree to Quanterix’s Terms of Use and Privacy Policy. In addition, you agree to receive information regarding Quanterix products and services. You will be able to unsubscribe at any time.